Human Papillomavirus Vaccines Session

Peter Szilagyi, MD, MPH
ACIP HPV Vaccines Work Group Chair

Advisory Committee on Immunization Practices
February 27, 2019
HPV vaccination policy issue being addressed by the Work Group

- Should HPV vaccination be recommended for persons aged 27 through 45 years who were not previously vaccinated?
Expanded age indication for 9-valent HPV vaccine

- Manufacturer filed a sBLA in April 2018 to expand the age indication for 9-valent HPV vaccine (9vHPV) from age 9–26 years to age 9–45 years
- Approved by FDA in October 2018
- 9-valent HPV vaccine is the only HPV vaccine currently available in the United States

sBLA, Supplemental Biologics License Application
Past ACIP HPV vaccine sessions, mid-adult vaccination

June 2018

- Overview and history of application for licensure in mid-adults
- HPV epidemiology, natural history and burden of disease
- Clinical trial data included in sBLA

October 2018

- Regulatory basis for licensure
- U.S. vaccination program
  - Coverage and impact on infection/disease
- HPV epidemiology and sexual behavior
- Post-licensure effectiveness studies
- Global HPV vaccination & vaccine supply
- GRADE
  - Efficacy, immunogenicity, safety
- Preliminary health economic analyses
- Policy considerations

Mid-adults, ages 27–45 years
sBLA, Supplemental Biologics License Application
ACIP HPV Vaccines Work Group – topics reviewed related to mid-adult vaccination since October 2018

- Impact modeling and health economic analyses
- HPV epidemiology and natural history
- Values and acceptability to stakeholders
- Recommendation options for consideration
Modeling and health economic analyses for mid-adult HPV vaccination

- Three models were initially providing evidence for this policy question
- All still going through CDC/ACIP economic review at the time of the October 2018 ACIP meeting
  - Differences in results across models – preliminary data presented
- Several Work Group calls have been devoted to this topic
Today’s HPV Vaccines Session

▪ Overview and Background
  Dr. Lauri Markowitz, CDC/NCIRD

▪ Impact and Cost Effectiveness, Mid-adult HPV Vaccination
  Dr. Marc Brisson, Laval University

▪ Overview of Health Economic Results from 4 Modeling Groups
  Dr. Harrell Chesson, CDC/NCHHSTP

▪ Mid-adult HPV Vaccination: Patient Values and Acceptability
  Dr. Nancy McClung, CDC/NCIRD

▪ Program and Vaccine Provider Surveys
  Dr. Elissa Meites, CDC/NCIRD

▪ Work Group Considerations
  Dr. Lauri Markowitz, CDC/NCIRD
ACIP HPV Vaccines Work Group

- **ACIP Members**
  - Peter Szilagyi (Chair)
  - Jose Romero
  - Kevin Ault

- **Ex Officio Members**
  - Jeff Roberts (FDA)
  - Joohee Lee (FDA)

- **CDC Lead**
  - Lauri Markowitz

- **Liaison Representatives**
  - Shelley Deeks (NACCI)
  - Linda Eckert (ACOG)
  - Sandra Fryhofer (ACP)
  - Amy Middleman (SAHM)
  - Chris Nyquist (AAP)
  - Sean O’Leary (PIDS)
  - Robin O’Meara (AAFP)
  - Patricia Whitley-Williams (NMA)
  - Jane Zucker (AIM)

- **Consultants**
  - Joseph Bocchini
  - Tamera Coyne-Beasley
  - John Douglas
  - Allison Kempe
  - Aimee Kreimer (NCI)
  - Debbie Saslow (ACS)
  - Rodney Willoughby
  - Rachel Winer

**CDC Contributors**

- Harrell Chesson
- Julianne Gee
- Elissa Meites
- Jeanne Santoli
- Mona Saraiya
- John Su
- Shannon Stokley
- Lakshmi Panagiotakogoulos
- Elizabeth Unger
- Charnetta Williams